A Phase 2a double blind, placebo-controlled study (NCT05104853) using a nano-particle, CNP-104 harboring a PDC-E2 peptide dispersed within a negatively charged polymer matrix of poly (lactic-co-glycolic acid) (PLGA) particle is in progress to evaluate its safety, tolerability, pharmacodynamics, and efficacy in PBC patients unresponsive to UDCA. This evidence concerns the gene DLAT and primary biliary cholangitis.